Del17p refers to the deletion of a part of chromosome 17. This deletion is associated with an aggressive course of multiple myeloma and often indicates resistance to certain therapies. It is considered a high-risk cytogenetic abnormality.
IGH breakapart refers to rearrangements involving the immunoglobulin heavy chain gene located on chromosome 14. These rearrangements are significant because they are often associated with a more aggressive form of multiple myeloma and can influence treatment decisions.
These genetic abnormalities are associated with changes in the behavior of multiple myeloma. For example, t(4;14) and t(14;16) are translocations that are associated with a poorer prognosis, while del13q is a common deletion in multiple myeloma.
The results of this test can help your doctor understand the genetic characteristics of your multiple myeloma. This information is critical for risk stratification and choosing the most appropriate treatment strategy for your condition.
No, fasting is not required for this test.
Yes, certain genetic abnormalities detected by this test, such as del17p, are known to be associated with resistance to specific therapies. This information can be invaluable in guiding treatment decisions.
Standard cytogenetics looks at the overall structure of chromosomes, while FISH analysis is more focused and uses fluorescent probes to look for specific genetic changes.
The bone marrow aspiration procedure can cause discomfort, but pain medication and local anesthesia are typically used to minimize pain.
No special preparation is needed. However, it is advisable to inform your doctor about any medications you are taking.
Bone marrow is preferred for this test as it provides a more concentrated population of plasma cells, which are the primary cells involved in multiple myeloma.
If the test results indicate high-risk genetic abnormalities, it's important to discuss your treatment options with your doctor, who may suggest more aggressive or novel therapies.
This test is usually performed at the time of diagnosis. It may be repeated if there is a change in your clinical condition or if your doctor needs updated information to make treatment decisions.
If no genetic abnormalities are detected, it could mean that your multiple myeloma has a more standard risk profile. However, it's important to note that the absence of abnormalities in this test does not rule out the presence of other genetic changes.
By understanding the genetic characteristics of multiple myeloma through Myeloma Cytogenetics-2 with CD138 Magnetic Bead Enrichment, you and your doctor are better equipped to make informed decisions regarding treatment strategies. It is important to discuss the results of this test in detail with your doctor to understand the implications for your specific case.